Cargando…

Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview

Primary brain tumors (PBTs) are some of the most difficult types of cancer to treat, and despite advancements in surgery, chemotherapy and radiotherapy, new strategies for the treatment of PBTs are needed, especially for those with poor prognosis such as inoperable/difficult-to-reach lesions or rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Cimini, Andrea, Ricci, Maria, Russo, Francesca, Egidi, Martina, Calabria, Ferdinando, Bagnato, Antonio, Schillaci, Orazio, Chiaravalloti, Agostino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470698/
https://www.ncbi.nlm.nih.gov/pubmed/34577572
http://dx.doi.org/10.3390/ph14090872
_version_ 1784574266809778176
author Cimini, Andrea
Ricci, Maria
Russo, Francesca
Egidi, Martina
Calabria, Ferdinando
Bagnato, Antonio
Schillaci, Orazio
Chiaravalloti, Agostino
author_facet Cimini, Andrea
Ricci, Maria
Russo, Francesca
Egidi, Martina
Calabria, Ferdinando
Bagnato, Antonio
Schillaci, Orazio
Chiaravalloti, Agostino
author_sort Cimini, Andrea
collection PubMed
description Primary brain tumors (PBTs) are some of the most difficult types of cancer to treat, and despite advancements in surgery, chemotherapy and radiotherapy, new strategies for the treatment of PBTs are needed, especially for those with poor prognosis such as inoperable/difficult-to-reach lesions or relapsing disease. In regard to the last point, malignant primary brain tumors remain some of the most lethal types of cancer. Nuclear medicine may provide exciting new weapons and significant contributions in the treatment of PBTs. In this review, we performed literature research in order to highlight the possible role of peptide receptor radionuclide therapy (PRRT) in the treatment of PBTs with radiolabeled molecules that bind with high-affinity transmembrane receptors such as somatostatin receptors (SSTRs), neurokinin type-1 receptor and prostate-specific membrane antigen (PSMA). These receptors are overexpressed in some cancer types such as gliomas, meningiomas, pituitary tumors and medulloblastomas. A comprehensive overview of possible applications in this field will be shown, providing knowledge about benefits, feasibility, developments and limitations of PRRT in this type of tumor, also revealing new advantages in the management of the disease.
format Online
Article
Text
id pubmed-8470698
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84706982021-09-27 Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview Cimini, Andrea Ricci, Maria Russo, Francesca Egidi, Martina Calabria, Ferdinando Bagnato, Antonio Schillaci, Orazio Chiaravalloti, Agostino Pharmaceuticals (Basel) Review Primary brain tumors (PBTs) are some of the most difficult types of cancer to treat, and despite advancements in surgery, chemotherapy and radiotherapy, new strategies for the treatment of PBTs are needed, especially for those with poor prognosis such as inoperable/difficult-to-reach lesions or relapsing disease. In regard to the last point, malignant primary brain tumors remain some of the most lethal types of cancer. Nuclear medicine may provide exciting new weapons and significant contributions in the treatment of PBTs. In this review, we performed literature research in order to highlight the possible role of peptide receptor radionuclide therapy (PRRT) in the treatment of PBTs with radiolabeled molecules that bind with high-affinity transmembrane receptors such as somatostatin receptors (SSTRs), neurokinin type-1 receptor and prostate-specific membrane antigen (PSMA). These receptors are overexpressed in some cancer types such as gliomas, meningiomas, pituitary tumors and medulloblastomas. A comprehensive overview of possible applications in this field will be shown, providing knowledge about benefits, feasibility, developments and limitations of PRRT in this type of tumor, also revealing new advantages in the management of the disease. MDPI 2021-08-29 /pmc/articles/PMC8470698/ /pubmed/34577572 http://dx.doi.org/10.3390/ph14090872 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cimini, Andrea
Ricci, Maria
Russo, Francesca
Egidi, Martina
Calabria, Ferdinando
Bagnato, Antonio
Schillaci, Orazio
Chiaravalloti, Agostino
Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview
title Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview
title_full Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview
title_fullStr Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview
title_full_unstemmed Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview
title_short Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview
title_sort peptide receptor radionuclide therapy and primary brain tumors: an overview
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470698/
https://www.ncbi.nlm.nih.gov/pubmed/34577572
http://dx.doi.org/10.3390/ph14090872
work_keys_str_mv AT ciminiandrea peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview
AT riccimaria peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview
AT russofrancesca peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview
AT egidimartina peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview
AT calabriaferdinando peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview
AT bagnatoantonio peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview
AT schillaciorazio peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview
AT chiaravallotiagostino peptidereceptorradionuclidetherapyandprimarybraintumorsanoverview